Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?

Rossi E, Schinzari G, Zizzari IG, Maiorano BA, Pagliara MM, Sammarco MG, Fiorentino V, Petrone G, Cassano A, Rindi G, Bria E, Blasi MA, Nuti M, Tortora G.

Cancers (Basel). 2019 Jul 26;11(8). pii: E1055. doi: 10.3390/cancers11081055. Review.

2.

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.

Botticelli A, Salati M, Di Pietro FR, Strigari L, Cerbelli B, Zizzari IG, Giusti R, Mazzotta M, Mazzuca F, Roberto M, Vici P, Pizzuti L, Nuti M, Marchetti P.

J Transl Med. 2019 Mar 27;17(1):99. doi: 10.1186/s12967-019-1847-x.

3.

Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets.

Napoletano C, Ruscito I, Bellati F, Zizzari IG, Rahimi H, Gasparri ML, Antonilli M, Panici PB, Rughetti A, Nuti M.

J Clin Med. 2019 Mar 18;8(3). pii: E380. doi: 10.3390/jcm8030380.

4.

Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells.

Dionisi M, De Archangelis C, Battisti F, Rahimi Koshkaki H, Belleudi F, Zizzari IG, Ruscito I, Albano C, Di Filippo A, Torrisi MR, Benedetti Panici P, Napoletano C, Nuti M, Rughetti A.

Front Immunol. 2018 Nov 5;9:2481. doi: 10.3389/fimmu.2018.02481. eCollection 2018.

5.

The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one.

Nuti M, Zizzari IG, Botticelli A, Rughetti A, Marchetti P.

Cancer Treat Rev. 2018 Nov;70:41-46. doi: 10.1016/j.ctrv.2018.07.016. Epub 2018 Jul 26. Review.

6.

The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.

Ruscito I, Darb-Esfahani S, Kulbe H, Bellati F, Zizzari IG, Rahimi Koshkaki H, Napoletano C, Caserta D, Rughetti A, Kessler M, Sehouli J, Nuti M, Braicu EI.

Gynecol Oncol. 2018 Jul;150(1):151-157. doi: 10.1016/j.ygyno.2018.05.006. Epub 2018 May 10.

PMID:
29753392
7.

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.

Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M.

Cancer Immunol Res. 2018 Jun;6(6):711-722. doi: 10.1158/2326-6066.CIR-17-0594. Epub 2018 Apr 26.

8.

Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets.

Ruscito I, Braicu EI, Gasparri ML, Zizzari IG.

Biomed Res Int. 2018 Mar 1;2018:6532019. doi: 10.1155/2018/6532019. eCollection 2018. No abstract available.

9.

Anisakis pegreffii impacts differentiation and function of human dendritic cells.

Napoletano C, Mattiucci S, Colantoni A, Battisti F, Zizzari IG, Rahimi H, Nuti M, Rughetti A.

Parasite Immunol. 2018 May;40(5):e12527. doi: 10.1111/pim.12527.

10.

CAR-T cells: the long and winding road to solid tumors.

D'Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M.

Cell Death Dis. 2018 Feb 15;9(3):282. doi: 10.1038/s41419-018-0278-6. Review.

11.

Tumor-Derived Microvesicles Modulate Antigen Cross-Processing via Reactive Oxygen Species-Mediated Alkalinization of Phagosomal Compartment in Dendritic Cells.

Battisti F, Napoletano C, Rahimi Koshkaki H, Belleudi F, Zizzari IG, Ruscito I, Palchetti S, Bellati F, Benedetti Panici P, Torrisi MR, Caracciolo G, Altieri F, Nuti M, Rughetti A.

Front Immunol. 2017 Sep 25;8:1179. doi: 10.3389/fimmu.2017.01179. eCollection 2017.

12.

Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells.

Napoletano C, Bellati F, Ruscito I, Pernice M, Zizzari IG, Caponnetto S, Tomao F, Frigerio L, Liberati M, Rughetti A, Caserta D, Panici PB, Nuti M.

Anticancer Res. 2016 Oct;36(10):5109-5116.

PMID:
27798870
13.

Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway.

Iudicone P, Fioravanti D, Cicchetti E, Zizzari IG, Pandolfi A, Scocchera R, Fazzina R, Pierelli L.

Hum Immunol. 2016 Dec;77(12):1239-1247. doi: 10.1016/j.humimm.2016.09.003. Epub 2016 Sep 9.

PMID:
27615504
14.

Potency testing of mesenchymal stromal cell growth expanded in human platelet lysate from different human tissues.

Fazzina R, Iudicone P, Fioravanti D, Bonanno G, Totta P, Zizzari IG, Pierelli L.

Stem Cell Res Ther. 2016 Aug 25;7(1):122. doi: 10.1186/s13287-016-0383-3.

15.

Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.

Antonilli M, Rahimi H, Visconti V, Napoletano C, Ruscito I, Zizzari IG, Caponnetto S, Barchiesi G, Iadarola R, Pierelli L, Rughetti A, Bellati F, Panici PB, Nuti M.

Int J Oncol. 2016 Apr;48(4):1369-78. doi: 10.3892/ijo.2016.3386. Epub 2016 Feb 8.

16.

MGL Receptor and Immunity: When the Ligand Can Make the Difference.

Zizzari IG, Napoletano C, Battisti F, Rahimi H, Caponnetto S, Pierelli L, Nuti M, Rughetti A.

J Immunol Res. 2015;2015:450695. doi: 10.1155/2015/450695. Epub 2015 Dec 29. Review.

17.

The Macrophage Galactose-Type C-Type Lectin (MGL) Modulates Regulatory T Cell Functions.

Zizzari IG, Martufi P, Battisti F, Rahimi H, Caponnetto S, Bellati F, Nuti M, Rughetti A, Napoletano C.

PLoS One. 2015 Jul 6;10(7):e0132617. doi: 10.1371/journal.pone.0132617. eCollection 2015.

18.

Microvesicle cargo of tumor-associated MUC1 to dendritic cells allows cross-presentation and specific carbohydrate processing.

Rughetti A, Rahimi H, Belleudi F, Napoletano C, Battisti F, Zizzari IG, Antonilli M, Bellati F, Wandall HH, Benedetti Panici P, Burchell JM, Torrisi MR, Nuti M.

Cancer Immunol Res. 2014 Feb;2(2):177-86. doi: 10.1158/2326-6066.CIR-13-0112-T. Epub 2013 Oct 28.

19.

Past, present and future strategies of immunotherapy in gynecological malignancies.

Bellati F, Napoletano C, Ruscito I, Visconti V, Antonilli M, Gasparri ML, Zizzari IG, Rahimi H, Palaia I, Rughetti A, Benedetti Panici P, Nuti M.

Curr Mol Med. 2013 May;13(4):648-69.

PMID:
22934850
20.

Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation.

Napoletano C, Zizzari IG, Rughetti A, Rahimi H, Irimura T, Clausen H, Wandall HH, Belleudi F, Bellati F, Pierelli L, Frati L, Nuti M.

Eur J Immunol. 2012 Apr;42(4):936-45. doi: 10.1002/eji.201142086.

21.

Monoclonal antibodies in gynecological cancer: a critical point of view.

Bellati F, Napoletano C, Gasparri ML, Visconti V, Zizzari IG, Ruscito I, Caccetta J, Rughetti A, Benedetti-Panici P, Nuti M.

Clin Dev Immunol. 2011;2011:890758. doi: 10.1155/2011/890758. Epub 2011 Dec 26. Review.

22.

HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.

Zizzari IG, Veglia F, Taurino F, Rahimi H, Quaglino E, Belleudi F, Riccardo F, Antonilli M, Napoletano C, Bellati F, Benedetti-Panici P, Torrisi MR, Frati L, Nuti M, Rughetti A.

J Mol Med (Berl). 2011 Dec;89(12):1231-40. doi: 10.1007/s00109-011-0794-7. Epub 2011 Aug 16.

23.

Immune effects of trastuzumab.

Nuti M, Bellati F, Visconti V, Napoletano C, Domenici L, Caccetta J, Zizzari IG, Ruscito I, Rahimi H, Benedetti-Panici P, Rughetti A.

J Cancer. 2011;2:317-23. Epub 2011 May 25.

Supplemental Content

Loading ...
Support Center